MGeneRx
MGeneRx is developing an artificial intelligence platform that identifies a child's risk for congenital birth defects using biometric analysis. The platform, created by rare disease experts, physicians, and engineers, aims to provide cost-effective screening by identifying phenotypes of genetic anomalies. Unlike common newborn DNA tests that detect only about 20 out of over 8,000 identified genetic disorders, MGeneRx's application has been evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions, achieving close to 90% accuracy in detecting syndromes. This technology offers instant results, supports early referral to specialized care, reduces high clinical costs, and expands outreach to underserved rural areas. The company collaborates with institutions like Children's National Hospital and the American Academy of Pediatrics.
MGeneRx
MGeneRx is developing an artificial intelligence platform that identifies a child's risk for congenital birth defects using biometric analysis. The platform, created by rare disease experts, physicians, and engineers, aims to provide cost-effective screening by identifying phenotypes of genetic anomalies. Unlike common newborn DNA tests that detect only about 20 out of over 8,000 identified genetic disorders, MGeneRx's application has been evaluated on thousands of pediatric patients from 28 countries with 128 different genetic conditions, achieving close to 90% accuracy in detecting syndromes. This technology offers instant results, supports early referral to specialized care, reduces high clinical costs, and expands outreach to underserved rural areas. The company collaborates with institutions like Children's National Hospital and the American Academy of Pediatrics.